Opinion
Video
Current Treatment of Patients with NF1 pLGG
Author(s):
The panel reviews ongoing clinical trials for non-BRAF V600E pediatric low-grade gliomas (pLGG), specifically highlighting the Phase III ACNS1831 and Phase III ACNS1833 studies, discussing their objectives, designs, and potential implications for future treatment strategies.
EP: 1.Overview of pLGG presentation and categorization
EP: 2.Molecular Characterization of pLGG
EP: 3.Less Common Molecular Alterations in pLGG and Testing Recommendations
EP: 4.Standard of care for frontline treatment of non-V600E-specific pLGG tumors
EP: 5.Ongoing clinical trials for frontline treatment of non-V600E-specific pLGG tumors
Now Viewing
EP: 6.Current Treatment of Patients with NF1 pLGG
EP: 7.Standard of Care Pptions Specific for Frontline Treatment of BRAF V600E-Mutated pLGG
EP: 8.Treatment Considerations for Progressive pLGG
EP: 9.Radiation and Targeted Therapies for Progressive pLGG
EP: 10.The Role of Tovorafenib in Treatment of Progressive pLGG
EP: 11.Clinical Trials to Increase Treatment Options in the Progressive Setting
EP: 12.Clinical scenario 1 - BRAFKIAA-1549 fusion
EP: 13.Alternatives and Considerations for Clinical Scenario 1
EP: 14.Clinical Scenario 2 - BRAFV600E
EP: 15.Potential Adverse Events With Targeted Therapies
EP: 16.Clinical Insights: Looking Forward for pLGG
Related Videos
Related Content
